With technology gained from its 2010 acquisition of Sloning
BioTechnology GmbH, MorphoSys
AG started from scratch to create Ylanthia, a new antibody library that
will launch this year to replace the company's aging HuCAL platform.
MorphoSys was built on the
success of HuCAL, an antibody phage display platform that launched in 1997. The
platform has produced 77 programs in active development, 19 of which are in
clinical testing.